Circulating Tumor DNA Clinical Trial
Official title:
Circulating Tumor DNA as a Novel Molecular Marker of Treatment Efficacy to Guide Targeted Maintenance Therapy for Patients With High Grade Serous Ovarian Cancer
This study is a prospective observational clinical trial. Patients who were diagnosed and treated for the first time were enrolled and their surgical pathology was confirmed to be high-grade serous ovarian cancer. At the same time, these patients will receive first-line maintenance treatment with PARP inhibitors after traditional chemotherapy. During the trial period, patients' plasma will be collected before surgery, after chemotherapy, during targeted maintenance therapy, and during disease progression, and ctDNA-specific genomes will be detected, and clinical data will be collected over the same period. It is expected that specific ctDNA can be used to predict the efficacy of PARP inhibitors in patients with ovarian cancer, and to detect the recurrence of the disease early.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05167604 -
Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
|
||
| Recruiting |
NCT05598528 -
Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
|
||
| Recruiting |
NCT04555369 -
The Value of ctDNA on Chemotherapy Efficacy for mCRC
|
N/A | |
| Not yet recruiting |
NCT03688035 -
Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
|
||
| Recruiting |
NCT03737539 -
Dynamic Monitoring of ctDNA Methylation to Predict Relapse in Colorectal Cancer After Radical Resection (POSTCA)
|
||
| Not yet recruiting |
NCT04511559 -
Methylation Analysis of Circulating Tumor DNA in Gastric Cancer
|
||
| Recruiting |
NCT03748680 -
IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT02620527 -
Concordance Between ctDNA Assay and FoundationOne
|
||
| Recruiting |
NCT05529615 -
Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer
|
N/A | |
| Recruiting |
NCT05601505 -
Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer
|
Phase 2 | |
| Recruiting |
NCT05161585 -
Evaluation of Circulating Tumor DNA Guided Surveillance Strategy of Stage III Colorectal Cancer: an Open, Prospective, Randomized Controlled Cohort Study
|
N/A | |
| Recruiting |
NCT05390112 -
Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization
|
||
| Recruiting |
NCT04966663 -
Using ctDNA to Determine Therapies for Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05801276 -
ctDNA Methylation for Detecting Ovarian Cancer
|
||
| Recruiting |
NCT05801263 -
ctDNA Methylation for Epithelial Ovarian Cancer
|
||
| Active, not recruiting |
NCT04276337 -
Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy
|
||
| Recruiting |
NCT05969938 -
Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology
|
||
| Completed |
NCT04456972 -
Reliability and Interest of Circulating Tumor DNA in Endometrial Cancers.
|
N/A | |
| Completed |
NCT03750175 -
OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -
|
||
| Recruiting |
NCT04457297 -
Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection
|
Phase 3 |